Chelmsford, Massachusetts–based Zoll says it marks the fifth FDA-approved LifeVest WCD to hit the market. It works seamlessly with the company’s recently launched next-generation LifeVest WCD garment.
LifeVest delivers effective, safe therapy for patients at risk of sudden cardiac death. Zoll touts the highest rates of WCD patient compliance based on peer-reviewed publications and real-world data. It competes in a market that features WCDs from the likes of Kestra Medical and Element Science, among others.
New features for the latest LifeVest include greater comfort with lightweight, athleisure-inspired performance-wear fabric. It also has soft plush straps, flat-lock stitching and the largest range of garment sizes to fit a range of chest measurements.
Zoll says this builds on other features added to LifeVest over the previous iterations. Those include easy-to-reach response buttons and a large touchscreen for easy interaction. The company also introduced an AI-enhanced algorithm in 2018 that reduced false alarms. LifeVest continues to incorporate AI into its latest generation.
“ZOLL is always innovating to ensure patients have protection from sudden cardiac death with a solution that seamlessly integrates into their lives outside of the hospital,” said Mike Blastick, president of Zoll Cardiac Management Solutions. “The latest LifeVest represents the next step in our mission, combining advanced technology with patient-centered design.”
